- 1 **Title:** White blood cells and severe COVID-19: a Mendelian randomization study
- 2
 3 Yitang Sun¹, Jingqi Zhou^{1,2}, Kaixiong Ye^{1,3,*}
- 4
- ⁵ ¹ Department of Genetics, Franklin College of Arts and Sciences, University of Georgia,
- 6 Athens, GA, USA
- ² School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai,
- 8 P.R. China
- 9 ³ Institute of Bioinformatics, University of Georgia, Athens, GA, USA
- 10

11 * Address for Correspondence:

- 12
- 13 Dr. Kaixiong Ye
- 14 Department of Genetics
- 15 University of Georgia
- 16 C220 Davison Life Sciences
- 17 120 East Green Street, Athens, GA 30602
- 18 Office: 706-542-5898
- 19 Fax: 706-542-3910
- 20 Email:

Kaixiong.Ye@uga.edu

21 Abstract

22

Background: The pandemic of coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly emerged
to seriously threaten public health. We aimed to investigate whether white blood cell
traits have potential causal effects on severe COVID-19 using Mendelian randomization
(MR).

28

Methods: To evaluate the causal associations between various white blood cell traits and severe COVID-19, we conducted a two-sample MR analysis with summary statistics from recent large genome-wide association studies.

32

Results: Our MR results indicated potential causal associations of white blood cell count, myeloid white blood cell count, and granulocyte count with severe COVID-19, with odds ratios (OR) of 0.84 (95% CI: 0.72-0.98), 0.81 (95% CI: 0.70-0.94), and 0.84 (95% CI: 0.71-0.99), respectively. Increasing eosinophil percentage of white blood cells was associated with a higher risk of severe COVID-19 (OR: 1.22, 95% CI: 1.03-1.45).

39

40 **Conclusions:** Our results suggest the potential causal effects of lower white blood cell 41 count, lower myeloid white blood cell count, lower granulocyte count, and higher 42 eosinophil percentage of white blood cells on an increased risk of severe COVID-19.

43

44 **Key Words:** COVID-19; white blood cells; eosinophil; Mendelian randomization

45

46 Background

47 Coronavirus disease 2019 (COVID-19) is caused by infection of a novel virus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS[®]CoV[®]2) [1]. SARS[®]CoV[®]2 48 49 has rapidly spread, causing damage or even death [2-4]. Besides age and gender, 50 some pre-existing conditions are also well-known to be associated with an increased 51 risk of severe COVID-19, such as cardiovascular disease, diabetes, chronic respiratory 52 disease, hypertension, and cancers [4-7]. Recently, genetic studies, including two genome-wide association studies (GWAS), have identified multiple genetic loci to be 53 54 associated with the susceptibility and severity of COVID-19 [8-10]. However, causal risk 55 factors for severe COVID-19 remain unclear. Identifying host factors predisposing 56 individuals to severe COVID-19 is urgently needed to improve primary prevention and to 57 develop treatment strategies.

58

Elevated white blood cell and neutrophil counts, and depleted lymphocyte count have 59 60 been repeatedly observed in COVID-19 patients with severe outcomes, and neutrophil-61 to-lymphocyte ratio have been proposed as a prognostic biomarker [1, 11-14]. However, 62 findings from recent observational studies are inconsistent and the exact roles of white 63 blood cells and its various subtypes in severe COVID-19 remain elusive [15-17]. Most 64 existing studies measured blood cell counts in patients with confirmed infection of 65 SARS-CoV-2 and as a result, the hematological indices could have been modified by 66 immune responses [18]. It is unknown if blood cell counts before infection are

67 associated with the risk of developing severe COVID-19. Even if white blood cells are 68 measured before infection, they are influenced by many exogenous and endogenous 69 factors (e.g., age, gender, disease status, and medications), which will confound the 70 observational associations [19, 20]. No previous research has been able to interrogate 71 the causal role of white blood cells in severe COVID-19.

72

73 While traditional observational associations often suffer from confounding, reverse 74 causality, and various biases, a complementary approach, Mendelian randomization 75 (MR), utilizes genetic variants as instrumental variables to approximate the lifetime 76 status of exposure and enable causal inference in observational data. The random 77 allocation of the allele at conception and the natural directional effects of genetic 78 variants empower MR estimates to be less plaqued by confounding and reverse 79 causality [21, 22]. In this study, we aimed to test the causal effects of 19 white blood cell 80 traits on severe COVID-19 by performing a two-sample MR analysis.

81 Methods

82 Study design and data source

83 A two-sample MR study was conducted to examine the causal effects of 19 white blood 84 cell traits on severe COVID-19. These blood cell traits were chosen based on a GWAS 85 meta-analysis in 173,480 European ancestry individuals across three cohorts, and their 86 summary statistics were available in the IEU OpenGWAS database [23, 24]. Genetic 87 instruments for each white blood cell trait were chosen based on the following criteria: 1) $p < 8.31 \times 10^{-9}$ for association with the exposure; and 2) linkage disequilibrium (LD) 88 clumping based on $r^2 > 0.001$. The data source and details for 19 white blood cell traits 89 90 are available in Supplementary Table 1. The instrument-outcome effects were retrieved 91 from the largest GWAS meta-analysis of COVID-19 to date, by the COVID-19 Host 92 Genetics Initiative (HGI, release 3, accessed on July 2, 2020) [10]. We used the 93 summary statistics based on the comparison of hospitalized COVID-19 patients (N = 94 (N = 897, 488).

95

96 Statistical analysis

97 The causal effect of a white blood cell trait on severe COVID-19 was evaluated using 98 the inverse variance-weighted (IVW) method with a multiplicative random-effects model 99 [22, 25, 26]. Horizontal pleiotropy occurs when SNPs exert a direct effect on the severe 100 COVD-19 through pathways other than the hypothesized exposure. To evaluate the 101 possible presence of horizontal pleiotropy, we calculated Cochran's Q statistic for 102 heterogeneity and conducted the intercept test associated with the MR-Egger method. 103 Additional sensitivity analyses were performed with MR-Egger [22, 26], weighted

median (WM) [27], and Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test [28]. The MR-Egger estimates allowed directional or unbalanced horizontal pleiotropic effects. The weighted median method provides robust causal estimates even when up to 50 % SNPs are invalid genetic instruments [27]. The MR-PRESSO test was utilized to correct for the presence of specific horizontal pleiotropic outlier variants via detected outlier removal [28]. All MR analyses were conducted in R with the TwoSampleMR package [23].

111

112 **Resources**

- 113 The COVID-19 Host Genetics Initiative: <u>https://www.covid19hg.org/</u>
- 114 The IEU OpenGWAS database: <u>https://gwas.mrcieu.ac.uk/</u>

115 Results

116 The counts of white blood cell, myeloid white blood cell, and granulocyte are

117 negatively associated with severe COVID-19

118 By applying a two-sample MR approach, we first investigated the causal associations of 119 the counts of white blood cell and its subpopulations with severe COVID-19. A relatively 120 large number of independent SNPs, ranging from 79 for basophil count to 185 for 121 monocyte count, were selected as genetic instruments for each blood cell count 122 (Supplementary Tables 2-11). Based on the IVW MR estimates under a multiplicative 123 random-effects model, we identified potentially causal, negative associations of white 124 blood cell count (OR = 0.84, CI: 0.72-0.98, p = 0.031), basophil count (OR = 0.75, CI: 125 0.58-0.96, p = 0.023), myeloid white blood cell count (OR = 0.81, CI: 0.70-0.94, p =126 0.0070), and granulocyte count (OR = 0.84, CI: 0.71-0.99, p = 0.040) with severe 127 COVID-19 (Fig. 1, Table 1). A suggestive negative association was also found for sum 128 neutrophil eosinophil counts (OR = 0.85, CI: 0.73-1.00, p = 0.051). No evidence of 129 heterogeneity in causal estimates was found by the Cochran Q statistic, and no 130 evidence of horizontal pleiotropy was reported by the MR-Egger intercept test, except 131 for basophil count (p = 0.036). Causal estimates from MR-Egger and WM MR revealed 132 broadly concordant effect directions, although they are mostly not statistically significant, 133 probably due to the reduced power of these two approaches [26] (Supplementary Fig. 1, 134 Supplementary Table 21). MR-PRESSO analysis did not identify any outlier SNPs and 135 yielded significant causal estimates for white blood cell count (p = 0.033), myeloid white 136 blood cell count (p = 0.0078), and granulocyte count (p = 0.041) (Supplementary Table 137 21). Taken together, we demonstrated that white blood cell count, myeloid white blood

cell count, and granulocyte count had consistent, negative effects on the risk of severeCOVID-19.

140

141 The percentage of eosinophil in white blood cell is positively associated with

142 severe COVID-19

We further investigated the causal associations of the percentages of specific white blood cells with severe COVID-19. As genetic instruments, we used 158 SNPs for eosinophil percentage, 63 SNPs for basophil percentage, 135 SNPs for the neutrophil percentage, 191 SNPs for monocyte percentage, and 135 SNPs for lymphocyte percentage (Supplementary Tables 12-16).

148

149 Genetically predicted higher eosinophil percentage of white blood cells (OR = 1.22, CI: 150 1.03-1.45, p = 0.023) was associated with increased risk of severe COVID-19 using 151 IVW with the random-effect model (Figure 1). The WM MR method and the MR-152 PRESSO analysis both revealed a consistent, positive effect (OR = 1.41, CI: 1.07-1.87, 153 p = 0.015; and OR = 1.22, CI: 1.03-1.45, p = 0.024; respectively. Supplementary Table 154 21). No pleiotropy or outlier SNPs were identified in the MR-Egger test and MR-155 PRESSO analysis. Cochran Q statistics indicated no heterogeneity among the genetic 156 instruments (Supplementary Table 21).

157

The percentage of eosinophil in granulocyte is positively associated with severeCOVID-19

160 We further focused on the granulocyte and evaluated if it specific compositions are 161 associated with severe COVID-19. As genetic instruments, there were 168 SNPs for 162 granulocyte percentage of myeloid white blood cells, 150 SNPs for eosinophil 163 percentage of granulocytes, 59 SNPs for basophil percentage of granulocytes, and 141 164 SNPs for the neutrophil percentage of granulocytes (Supplementary Tables 17-20). Our 165 results found suggestive evidence for a risk-increasing effect of eosinophil percentage 166 of granulocytes on severe COVID-19 (OR = 1.18, CI: 1.00-1.39, p = 0.053). The WM 167 MR method and the MR-PRESSO analysis both revealed a consistent positive effect 168 (OR = 1.35, CI: 1.03-1.75, p = 0.029; and OR = 1.18, CI: 1.00-1.39, p = 0.055;169 respectively). No evidence of heterogeneity and pleiotropy was found. No statistically 170 significant causal associations were identified for other specific granulocyte percentages 171 (Figure 1 and Supplementary Table 21).

172 **Discussion**

To our knowledge, this is the first MR study evaluating the causal roles of white blood cell traits in severe COVID-19 risk. Overall, our results suggest potential causal protective effects of increasing white blood cell count, myeloid white blood cell count, and granulocyte count on severe COVID-19. Our novel findings also include that genetically predicted higher eosinophil percentage in white blood cells or in granulocytes was associated with a higher risk of severe COVID-19.

179

180 Previous observational studies have frequently pointed out increased white blood cell 181 count in the severe COVID-19 patients, when compared to healthy controls or mild 182 COVID-19 patients [1, 11, 12, 29]. However, there are also reports that normal or 183 decreased white blood cell count is more common in COVID-19 patients when 184 compared to the reference range or healty controls [10, 15-17, 30-32]. Our MR analysis 185 showed that lower white blood cell count, myeloid white blood cell count, and 186 granulocyte count may play a causal role in increasing the risk of severe COVID-19. The mechanism by which they contribute to severe COVID-19 remains unclear. Immune 187 188 system disorders have been suspected of playing roles in severe COVID-19 risk [33, 189 34]. The complete elucidation of the potential mechanism warrants further investigation.

190

Persistent eosinopenia after admission was associated with COVID-19 risk in previous retrospective and prospective observational studies [12, 15, 31, 32, 35-37]. There are also reports that eosinophil remains stable in severe COVID-19 patients [13, 29, 38, 39]. A multiparametric flow cytometry analysis found that high eosinophil count was

195 associated with an increased risk of severe COVID-19 [13]. Another observational study 196 suggested that increasing eosinophil count might be an indicator of COVID-19 197 improvement [40]. Our MR analysis supported that high eosinophil percentage of white 198 blood cells may be causal in increasing the risk of severe COVID-19 [40, 41], calling for 199 future mechanistic studies.

200

201 Lymphopenia, as a response to viral infection, has been frequently associated with 202 severe COVID-19 risk [1, 2, 13, 29, 41-51]. However, we did not detect a causal effect 203 of lymphocyte count on severe COVID-19. This discrepancy may reflect reverse 204 causality in retrospective and prospective observational studies, with depleted 205 lymphocyte count as a result of immune response to SARS²CoV²2 infection [52]. Due 206 to the limited number of SNPs associated with severe COVID-19, performing reverse 207 MR analyses between severe COVID-19 and white blood cell traits is challenging. Using 208 linkage disequilibrium (LD) assessment, only one SNP at locus 3p21.31 was retained in 209 the previously published genome-wide significant SNPs [10]. We recently showed that 210 SNPs at this locus are associated with multiple blood cell traits, suggesting they may 211 have pleiotropic effects and are not suitable to be used as genetic instruments [53]. As 212 more COVID-19-associated SNPs are identified in the future, reverse MR analysis will 213 be valuable to understand the effect of COVID-19 on blood cell traits.

214

215 One assumption of MR is that the instrumental variable influences severe COVID-19 216 risk only through its effect on a specific white blood cell trait. The Cochran Q statistic did 217 not reveal heterogeneity among our genetic instruments, and the MR-Egger intercept

- test also indicated no presence of pleiotropic effects except those for basophil count.
- 219 Our MR study was performed with strong instrumental variables and adequate statistical
- 220 power, and we have conducted extensive sensitivity analyses. Still, we emphasize that
- 221 our results should be interpreted with caution and future studies are needed to elucidate
- the mechanistic roles of white blood cell traits in severe COVID-19.

223 Conclusions

- 224 Our results suggest that lower white blood cell count, lower myeloid white blood cell
- count, lower granulocyte count, and higher eosinophil percentage of white blood cells
- are causally associated with an increased risk of severe COVID-19.

227 List of abbreviations

- 228 COVID-19: coronavirus disease 2019
- 229 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- 230 MR: Mendelian randomization
- 231 GWAS: genome-wide association studies
- 232 SNPs: single nucleotide polymorphisms
- 233 LD: linkage disequilibrium
- HGI: Host Genetics Initiative
- 235 IEU: Integrative Epidemiology Unit
- 236 IVW: inverse variance-weighted
- 237 WM: weighted median
- 238 MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier

239 **Declarations**

240 Ethics approval and consent to participate

- 241 Ethical approval from the North West Multi-Centre Research Ethics Committee and
- written informed consent from all participants were obtained.

243

- 244 **Consent for publication**
- Not applicable.

246

- 247 Availability of data and materials
- All data generated or analyzed during this study are included in this published article
- and this supplementary information files.

250

251 **Competing interests**

252 The authors declare that they have no competing interests.

253

254 Funding

- 255 KY is supported by the University of Georgia Research Foundation. Funding sources
- had no involvement in the conception, design, analysis, or presentation of this work.

257

258 Authors' contributions

- 259 YS, JZ, and KY conceived the study. YS performed data analysis and prepared
- visualizations. YS, JZ, and KY interpreted the results. YS and KY wrote the first draft of

- the manuscript. All authors critically read, revised, and approved the final version of the
- 262 manuscript.
- 263

264 Acknowledgments

- 265 We would like to express our gratitude to all other Ye lab members for stimulating
- discussions.
- 267

268 **ReferencesUncategorized References**

269 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al: 1. 270 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in 271 Wuhan, China: a retrospective cohort study. Lancet 2020, 395(10229):1054-1062. 272 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al: 2. 273 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 274 Lancet 2020, **395**(10223):497-506. 275 Wenham C, Smith J, Morgan R, Gender, Group C-W: COVID-19: the gendered 3. 276 impacts of the outbreak. Lancet 2020, 395(10227):846-848. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, 277 4. 278 Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F et al: COVID-19 and the 279 cardiovascular system: implications for risk assessment, diagnosis, and 280 treatment options. Cardiovasc Res 2020, 116(10):1666-1687. 281 Teng Y, Xu J, Zhang Y, Liu Z, Zhang S: Mendelian randomization in COVID-19: 5. 282 Applications for cardiovascular comorbidities and beyond. *EBioMedicine* 2020, **57**:102847. 283 284 Wu Z, McGoogan JM: Characteristics of and Important Lessons From the 6. 285 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 286 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 287 2020. 288 Rao S, Lau A, So HC: Exploring Diseases/Traits and Blood Proteins 7. 289 Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A 290 Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-291 Related Traits. Diabetes Care 2020, 43(7):1416-1426. 292 van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere 8. T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M et al: 293 294 Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA 295 2020. 296 Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, 9. 297 Fernandez J, Prati D, Baselli G, Asselta R et al: Genomewide Association Study of 298 Severe Covid-19 with Respiratory Failure. N Engl J Med 2020. 299 Initiative C-HG: The COVID-19 Host Genetics Initiative, a global initiative to 10. 300 elucidate the role of host genetic factors in susceptibility and severity of the 301 SARS-CoV-2 virus pandemic. Eur J Hum Genet 2020, 28(6):715-718. 302 Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q et al: 11. 303 Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-304 19 in Wuhan, China. JAMA Cardiol 2020, 5(7):802-810. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W 305 12. 306 et al: Dysregulation of Immune Response in Patients With Coronavirus 2019 307 (COVID-19) in Wuhan, China. Clin Infect Dis 2020, 71(15):762-768. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman 308 13. 309 AR, Agyekum RS, Mathew D, Baxter AE, Vella LA et al: Comprehensive mapping of 310 immune perturbations associated with severe COVID-19. Sci Immunol 2020, 5(49). 311 Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R et al: 14. 312 Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 313 coronavirus disease in the early stage. J Transl Med 2020, 18(1):206.

314 15. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M: The role of peripheral blood 315 eosinophil counts in COVID-19 patients. Allergy 2020. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, 316 16. 317 Li CH et al: Clinical characteristics of novel coronavirus cases in tertiary hospitals 318 in Hubei Province. Chin Med J (Engl) 2020, 133(9):1025-1031. 319 17. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, 320 Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA: Hematological findings 321 and complications of COVID-19. Am J Hematol 2020, 95(7):834-847. 322 18. Siedlinski M. Jozefczuk E. Xu X. Teumer A. Evangelou E. Schnabel RB. Welsh P. 323 Maffia P, Erdmann J, Tomaszewski M et al: White Blood Cells and Blood Pressure: 324 A Mendelian Randomization Study. Circulation 2020, 141(16):1307-1317. 325 Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S et al: Viral 19. 326 and host factors related to the clinical outcome of COVID-19. Nature 2020, 327 **583**(7816):437-440. 328 Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, Zeng S, Ding X, Nie H: Clinical 20. 329 features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis. Eur J Clin Microbiol Infect Dis 2020. 330 331 Davies NM, Holmes MV, Davey Smith G: Reading Mendelian randomisation 21. 332 studies: a guide, glossary, and checklist for clinicians. BMJ 2018, 362:k601. Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M, Hartwig F, 333 22. 334 Holmes M, Minelli C, Relton C et al: Guidelines for performing Mendelian 335 randomization investigations [version 2; peer review: 1 approved, 1 approved 336 with reservations]. Wellcome Open Research 2020, 4(186). 337 23. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, 338 Burgess S, Bowden J, Langdon R et al: The MR-Base platform supports systematic 339 causal inference across the human phenome. Elife 2018, 7. 340 Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, 24. 341 Riveros-Mckay F, Kostadima MA et al: The Allelic Landscape of Human Blood Cell 342 Trait Variation and Links to Common Complex Disease. Cell 2016, 167(5):1415-343 1429 e1419. 344 25. Burgess S, Butterworth A, Thompson SG: Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013, 345 346 **37**(7):658-665. 347 Bowden J, Davey Smith G, Burgess S: Mendelian randomization with invalid 26. 348 instruments: effect estimation and bias detection through Egger regression. Int J 349 Epidemiol 2015, 44(2):512-525. Bowden J, Davey Smith G, Haycock PC, Burgess S: Consistent Estimation in 350 27. 351 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol 2016, 40(4):304-314. 352 353 Verbanck M. Chen CY. Neale B. Do R: Detection of widespread horizontal 28. 354 pleiotropy in causal relationships inferred from Mendelian randomization between 355 complex traits and diseases. Nat Genet 2018, 50(5):693-698. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD: 356 29. 357 Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. 358 Allergy 2020, 75(7):1730-1741.

30. 359 Zhou Y, Fu B, Zheng X, Wang D, Zhao C, gi Y, Sun R, Tian Z, Xu X, Wei H: 360 Pathogenic T cells and inflammatory monocytes incite inflammatory storm in 361 severe COVID-19 patients. Natl Sci Rev 2020:nwaa041. 362 31. Sun DW, Zhang D, Tian RH, Li Y, Wang YS, Cao J, Tang Y, Zhang N, Zan T, Gao L et al: The underlying changes and predicting role of peripheral blood 363 364 inflammatory cells in severe COVID-19 patients: A sentinel? Clin Chim Acta 2020, 365 **508**:122-129. 366 32. Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, Xu L, Lei S, Pan A, Wang L et al: 367 Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients 368 in fever clinic: A retrospective case-control study. EClinicalMedicine 2020, 369 **23**:100375. 370 Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A, 33. 371 Ostro R, Banovcin P: Immune Parameters and COVID-19 Infection - Associations 372 With Clinical Severity and Disease Prognosis. Front Cell Infect Microbiol 2020, 373 **10**:364. 374 34. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Bruggen MC, O'Mahony L, Gao Y, Nadeau K, Akdis CA: Immune response to SARS-CoV-2 and 375 376 mechanisms of immunopathological changes in COVID-19. Allergy 2020, 377 **75**(7):1564-1581. Wang D, Li R, Wang J, Jiang Q, Gao C, Yang J, Ge L, Hu Q: Correlation 378 35. 379 analysis between disease severity and clinical and biochemical characteristics of 380 143 cases of COVID-19 in Wuhan, China: a descriptive study. BMC Infect Dis 2020, 381 **20**(1):519. 382 Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, Liu W, Tu S, Zhang M, 36. 383 Wang Q et al: Correlation Analysis Between Disease Severity and Inflammation-384 related Parameters in Patients with COVID-19 Pneumonia. 385 2020:2020.2002.2025.20025643. Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH: Eosinopenia 386 37. 387 and COVID-19. J Am Osteopath Assoc 2020. 388 Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu 38. 389 JG, Chen L et al: Epidemiologic and clinical characteristics of 91 hospitalized 390 patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case 391 series. QJM 2020, 113(7):474-481. 392 Lippi G, Henry BM: Eosinophil count in severe coronavirus disease 2019. 39. 393 *QJM* 2020, **113**(7):511-512. 394 Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J: Patients of 40. COVID-19 may benefit from sustained Lopinavir-combined regimen and the 395 396 increase of Eosinophil may predict the outcome of COVID-19 progression. Int J 397 Infect Dis 2020, 95:183-191. 398 41. Sun S. Cai X. Wang H. He G. Lin Y. Lu B. Chen C. Pan Y. Hu X: Abnormalities 399 of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin 400 *Chim Acta* 2020, **507**:174-180. 401 Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle 42. 402 L, Moreira A, Park MD et al: Immunology of COVID-19: Current State of the Science. 403 Immunity 2020, 52(6):910-941.

404 43. Rothan HA, Byrareddy SN: The epidemiology and pathogenesis of 405 coronavirus disease (COVID-19) outbreak. J Autoimmun 2020, 109:102433. 406 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong 44. 407 Y et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel 408 Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020, 323(11):1061-1069. 409 Ding Q, Lu P, Fan Y, Xia Y, Liu M: The clinical characteristics of pneumonia 45. 410 patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020. 411 412 Guan WJ. Ni ZY. Hu Y. Liang WH. Ou CQ. He JX. Liu L. Shan H. Lei CL. Hui 46. 413 DSC et al: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J 414 Med 2020, 382(18):1708-1720. 415 Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D: Early Clinical and CT 47. 416 Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. AJR Am J 417 Roentgenol 2020, 215(2):338-343. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J et 418 48. 419 al: Clinical characteristics and imaging manifestations of the 2019 novel 420 coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, 421 China. J Infect 2020, 80(4):388-393. 422 Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL, Lin MG, Mu XD: 49. 423 [Clinical features of 2019 novel coronavirus pneumonia in the early stage from a 424 fever clinic in Beijing]. Zhonghua Jie He He Hu Xi Za Zhi 2020, 43(0):E013. 425 Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, 50. 426 Huang K, Zeng QT: [Clinical characteristics and outcomes of 112 cardiovascular 427 disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020, 428 **48**(6):450-455. 429 Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong 51. 430 Y et al: Clinical features and treatment of COVID-19 patients in northeast 431 Chongging. J Med Virol 2020, 92(7):797-806. 432 52. Sattar N, Preiss D: Reverse Causality in Cardiovascular Epidemiological 433 Research: More Common Than Imagined? Circulation 2017, 135(24):2369-2372. 434 Zhou J, Sun Y, Huang W, Ye K: Altered blood cell traits underlie a major 53. 435 genetic locus of severe COVID-19. 2020:2020.2009.2009.20191700. 436

437 Tables

Table 1. Causal associations between white blood cell traits and severe COVID-19
based on random-effects IVW MR estimation.

440

441 Figure legends

442 Figure 1. Odds ratios for associations between genetically predicted risk factors and 443 severe COVID-19. Analyses were done with the inverse variance-weighted (IVW) 444 method with a multiplicative random-effects model. Effect estimates express the change 445 in odds ratio (OR) per standard deviation (SD) increment in white blood cell traits, error 446 bars indicate 95% confidence intervals. WBC#: White blood cell count; EO#: Eosinophil 447 count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; 448 LYMPH#: Lymphocyte count: MYELOID#: Myeloid white blood cell count: GRAN#: 449 Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: 450 Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; 451 BASO%: Basophil percentage of white blood cells; NEUT%: Neutrophil percentage of 452 white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: 453 Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte 454 percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of 455 granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: 456 Neutrophil percentage of granulocytes.

457 Supplemental Data

- 458 Supplementary Table 1. Summary of GWAS information for white blood cell 459 phenotypes
- 460 Supplementary Table 2. 167 SNPs used IVs in MR analyses testing effect of white
- 461 blood cell count on severe COVID-19 risk.
- 462 Supplementary Table 3. 169 SNPs used IVs in MR analyses testing effect of eosinophil
- 463 count on severe COVID-19 risk.
- 464 Supplementary Table 4. 79 SNPs used IVs in MR analyses testing effect of basophil
- 465 count on severe COVID-19 risk.
- 466 Supplementary Table 5. 140 SNPs used IVs in MR analyses testing effect of neutrophil
- 467 count on severe COVID-19 risk.
- 468 Supplementary Table 6. 185 SNPs used IVs in MR analyses testing effect of monocyte
- 469 count on severe COVID-19 risk.
- 470 Supplementary Table 7. 160 SNPs used IVs in MR analyses testing effect of 471 lymphocyte count on severe COVID-19 risk.
- 472 Supplementary Table 8. 146 SNPs used IVs in MR analyses testing effect of myeloid
- 473 white blood cell count on severe COVID-19 risk.
- 474 Supplementary Table 9. 144 SNPs used IVs in MR analyses testing effect of 475 granulocyte count on severe COVID-19 risk.
- 476 Supplementary Table 10. 139 SNPs used IVs in MR analyses testing effect of sum
 477 neutrophil eosinophil counts on severe COVID-19 risk.
- 478 Supplementary Table 11. 142 SNPs used IVs in MR analyses testing effect of sum
- 479 basophil neutrophil counts on severe COVID-19 risk.

- 480 Supplementary Table 12. 158 SNPs used IVs in MR analyses testing effect of 481 eosinophil percentage of white blood cells on severe COVID-19 risk.
- 482 Supplementary Table 13. 63 SNPs used IVs in MR analyses testing effect of basophil
- 483 percentage of white blood cells on severe COVID-19 risk.
- 484 Supplementary Table 14. 135 SNPs used IVs in MR analyses testing effect of neutrophil
- 485 percentage of white blood cells on severe COVID-19 risk.
- 486 Supplementary Table 15. 191 SNPs used IVs in MR analyses testing effect of monocyte
- 487 percentage of white blood cells on severe COVID-19 risk.
- 488 Supplementary Table 16. 135 SNPs used IVs in MR analyses testing effect of 489 lymphocyte percentage of white blood cells on severe COVID-19 risk.
- 490 Supplementary Table 17. 168 SNPs used IVs in MR analyses testing effect of 491 granulocyte percentage of myeloid white blood cells on severe COVID-19 risk.
- 492 Supplementary Table 18. 150 SNPs used IVs in MR analyses testing effect of 493 eosinophil percentage of granulocytes on severe COVID-19 risk.
- Supplementary Table 19. 59 SNPs used IVs in MR analyses testing effect of basophil
 percentage of granulocytes on severe COVID-19 risk.
- 496 Supplementary Table 20. 141 SNPs used IVs in MR analyses testing effect of neutrophil
- 497 percentage of granulocytes on severe COVID-19 risk.
- Supplementary Table 21. MR estimates from each method of assessing the causal
 effects of white blood cells on severe COVID-19 risk.
- 500 Supplementary Figure 1. Scatter plots of the genetic associations of white blood cell 501 count (A), or myeloid white blood cell count (B), or granulocyte count (C), or basophil
- 502 count (D) or eosinophil percentage in white blood cells (E) associated SNPs against the

503 genetic associations of severe COVID-19. The slopes of each line represent the causal 504 association using different MR methods. The light blue line represents the randomeffects inverse variance-weighted estimate, the dark blue line represents the MR-Egger 505 506 estimate, and the green line represents the weighted median estimate.

Tables

 Table 1. Causal associations between white blood cell traits and severe COVID-19 based on random-effects IVW MR estimation.

Exposure	Number	Odds ratio	95% Cl	P-value	Heterogenity	MR-Egger intercept
	of SNPs				P-value	test P-value
WBC#	167	0.84	0.72, 0.98	0.031	0.847	0.406
EO#	169	1.15	0.98, 1.36	0.086	0.188	0.485
BASO#	79	0.75	0.58, 0.96	0.023	0.570	0.037
NEUT#	140	0.87	0.74, 1.04	0.119	0.804	0.631
MONO#	185	0.93	0.83, 1.06	0.285	0.592	0.714
LYMPH#	160	0.94	0.79, 1.12	0.486	0.145	0.875
MYELOID#	146	0.81	0.70, 0.94	0.0070	0.974	0.901
GRAN#	144	0.84	0.71, 0.99	0.040	0.868	0.378
(NEUT+EO)#	139	0.85	0.73, 1.00	0.051	0.941	0.470
(BASO+NEUT)#	142	0.87	0.74, 1.03	0.098	0.873	0.408
EO%	158	1.22	1.03, 1.45	0.023	0.209	0.808
BASO%	63	0.82	0.64, 1.05	0.122	0.821	0.063

NEUT%	135	1.15	0.94, 1.40	0.169	0.550	0.105
MONO%	191	0.95	0.84, 1.08	0.457	0.656	0.388
LYMPH%	135	1.06	0.87, 1.30	0.548	0.380	0.859
GRAN%MYELOID	168	1.07	0.94, 1.22	0.325	0.894	0.746
EO%GRAN	150	1.18	1.00, 1.39	0.053	0.647	0.866
BASO%GRAN	59	0.84	0.65, 1.09	0.182	0.768	0.117
NEUT%GRAN	141	0.85	0.71, 1.02	0.083	0.327	0.861

WBC#: White blood cell count; EO#: Eosinophil count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#: Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; NEUT%: Neutrophil percentage of white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: Neutrophil percentage of granulocytes.

